ASH-David M. Goldenberg Clinical Research Training Institute Abstract Achievement Award
The ASH-David M. Goldenberg Clinical Research Training Institute Abstract Achievement Award is part of the ASH Abstract Achievement Award program. This annual award is granted to four CRTI alumni who is a first author and presenter of a high scoring abstract.
The ASH-David M. Goldenberg Clinical Research Training Institute Abstract Achievement Award includes four different categories:
- Classical Hematology
- Malignant Hematology
- International
- Access, Representation, and Population Health.
Each recipient shall receive a $5,000 honorarium.
How to Apply
To be eligible for this award, you must apply a content tag pertaining to one of the four categories (excepting the International category, which is evaluated based on whether the candidate is located outside of the United States). You must be a current participant or have participated in the past five years in one of the CRTI programs:
Recipients
Award Recipients
2026
Classical
Pedro Prata, MD, PhD
Centre Hospitalier Universitaire à Limoges
Somatic myeloid mutation landscape and clinical impact of next-generation sequencing in 909 treatment-naïve patients with immune aplastic anemia
Malignant
Yannis Valtis, MD
Memorial Sloan Kettering Cancer Center
Low disease burden is associated with favorable toxicity and outcomes among Pts receiving obecabtagene autoleucel for B-ALL in the real world: A rocca analysis
International
Angela Consagra, MD
University of Florence
Outcomes after luspatercept failure in lower-risk myelodysplastic neoplasms
Access Representation, and Population Health
Alfonso Molina, MD, MPH
University of California, San Francisco
ACCESS-T: A Phase 1 trial of orca-T with dual-agent tacrolimus/ruxolitinib prophylaxis for myeloablative HLA-mismatched allogeneic HCT
2025
Classical
Luke Smart,
University of Cincinnati
Benefits of hydroxyurea in hemoglobin SC: Results of the open-label phase of the prospective identification of variables as outcomes for treatment (PIVOT) trial
Malignant
Alfred Chung,
University of California, San Francisco
Minimal residual disease dynamics in post-transplant patients with newly diagnosed multiple myeloma who received daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in the auriga study
International
Nicholas Chornenki
University of Toronto
Grip strength predicts overall survival of patients with myelodysplastic syndrome in a multivariable model
Access, Representation, and Population Health
Lauren Merz,
University of Michigan
Multicenter assessment of absolute neutrophil counts (ANC) and white blood cell counts (WBC) in healthy participants with the erythrocyte duffy null phenotype or genotype
2024
Classical
Hanny Al-Samkari, MD
Massachussetts General Hospital
A Randomized, Placebo-Controlled, Multicenter Proof-of-Concept (POC) Study to Assess the Safety and Efficacy of the Novel Allosteric AKT Inhibitor, VAD044, in Adults with Hereditary Hemorrhagic Telangiectasia (HHT)
Malignant
Urvi A. Shah, MD
Memorial Sloan Kettering Cancer Center
A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
International
Alexia Gonzalez, MD
Universidad Autónoma de Nuevo León
Lowering Conditioning Intensity in Fit Adolescents and Adults with Lymphoblastic Leukemia without Residual Disease Undergoing Transplantation: A Proof of Concept
Access, Representation, and Population Health
Senthil Sukumar, MD, MSc
Baylor College of Medicine
More Than ADAMTS13: The Impact of Area Deprivation on Major Adverse Cardiovascular Events in Ittp Survivors